Ticho Barry 4

What Happened

• Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), had derivative awards (RSUs) convert into 33,850 shares on March 15, 2026 (13,100 + 10,000 + 10,750). The filing shows the shares were both "acquired" by conversion and "disposed" the same date. Reported exercise/conversion price per share is $0.00 and the filing lists $0 total value for these entries.

Key Details

• Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (timely filing).
• Reported price/value: $0.00 per share; $0 total as reported for these derivative conversions.
• Shares affected: 33,850 shares converted and 33,850 shares disposed (split across three award lines).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes: F1–F4 indicate these were restricted stock units (RSUs) that convert 1 RSU = 1 share and vest in quarterly/annual tranches (1/4 of award annually beginning March 15 of 2024, 2025 and 2026 as applicable).
• Transaction type/code: Reported under derivative exercise/conversion (Form 4 code M).

Context

• These entries reflect RSU settlement (conversion of RSUs into shares) and immediate disposition of the resulting shares on the same date. The filing does not state the nature of the disposition (sale, transfer, or tax-withholding) or any proceeds. For retail investors: conversions of RSUs followed by same-day dispositions are common for vesting and payroll/tax-related actions and do not by themselves indicate the insider's market view.